Sign in
Taking peoplePhase 2

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

Key facts

Who runs it
Guangdong Hengrui Pharmaceutical Co., Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
75 people, planned
Started
31 Dec 2025
Expected to end
Sept 2027
Type of study
Interventional, 3 groups
Treatments tested
  • SHR-2173 injection
Record updated
26 January 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Age 18-75 years, regardless of gender
  • Weight ≥40.0 kg at screening
  • Diagnosed as primary membranous nephropathy through kidney biopsy

Who cannot take part

  • Subjects developed rapidly progressive glomerulonephritis or required kidney transplantation
  • Subjects who have undergone kidney dialysis in the previous 12 months or are expected to require dialysis during the study period
  • Subjects who have undergone major surgery within the previous 3 months, or plan to undergo major surgery during the study period
  • Subjects who have a malignant tumor or a history of malignant tumor
  • Secondary membranous nephropathy

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy

The 3 groups in the trial

  • Treatment group ATreatment being tested

    Treatment: SHR-2173 injection

  • Treatment group BTreatment being tested

    Treatment: SHR-2173 injection

  • Treatment group CTreatment being tested

    Treatment: SHR-2173 injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07289763, who can take part
Record updated
26 January 2026